University of Toronto has described histone deacetylase 6 (HDAC6) inhibitors reported to be useful for the treatment of cancer and neurological disorders.
Shanghai Allist Pharmaceuticals Co. Ltd. has divulged protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.
Suzhou Kintor Pharmaceuticals Inc. has identified protein degradation inducers reported to be useful for the treatment of cancer, viral infection, cardiovascular and cerebrovascular disorders.
Nerviano Medical Sciences Srl has synthesized Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer, diabetic nephropathy, organ transplant rejection, arthritis, fibrosis, inflammation, neurodegeneration and metabolic diseases.
Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd., has received approval from the FDA and China’s National Medical Products Administration (NMPA) to conduct clinical trials with SIM-0500 in patients with relapsed or refractory multiple myeloma.
Transcode Therapeutics Inc. has reported promising proof-of-concept laboratory studies in human cells, advancing its strategic partnership with Akribion Genomics AG.
Eilean Therapeutics LLC has announced clearance by the Human Research Ethics Committee in Australia for a first-in-human phase I trial of balamenib (ZE63-0302), an oral small-molecule inhibitor of the menin-KMT2A interaction.
Researchers from Shanghai Institute of Materia Medica of the Chinese Academy of Sciences and affiliated organizations published preclinical data for a new class of mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitors being developed as candidates for the treatment of lymphoma.
Kymera Therapeutics Inc. has described proteolysis targeting chimeras (PROTAC) compounds comprising an E3 ubiquitin ligase cereblon (CRBN)-binding moiety covalently linked to a cyclin-dependent kinase 2 (CDK2)-targeting moiety through a linker.
RSS
